Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Incyte divulges new ACVR1 inhibitors

Jan. 5, 2022

Activation of ATF4 is required for DLBCL growth

Jan. 5, 2022

Garvan Institute awarded grant to investigate new treatment approach for pancreatic cancer

Jan. 4, 2022

PLCbeta4 blockade is a potential approach for treating uveal melanoma

Jan. 4, 2022

Novel allosteric inhibitor of tumor-promoting PPI between AIMP2-DX2 and HSP70

Jan. 4, 2022

Roche identifies new ENPP2 inhibitors

Jan. 4, 2022

Chinese researchers synthesize new SOS1 inhibitors

Jan. 4, 2022

Medshine Discovery discloses EZH2 inhibitors

Jan. 4, 2022

YAP1 promotes salivary gland regeneration after injury

Jan. 4, 2022

Siglec-15 promotes osteosarcoma tumor progression

Jan. 3, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...